Cybin Inc. (NYSE:CYBN - Get Free Report)'s stock price gapped down prior to trading on Monday . The stock had previously closed at $9.78, but opened at $9.30. Cybin shares last traded at $9.70, with a volume of 26,558 shares.
Analyst Ratings Changes
A number of equities research analysts have weighed in on the company. Canaccord Genuity Group decreased their price objective on Cybin from $114.00 to $96.00 and set a "buy" rating on the stock in a report on Monday, September 23rd. HC Wainwright reiterated a "buy" rating and issued a $5.00 price target on shares of Cybin in a research report on Friday, August 23rd. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Cybin in a report on Wednesday, July 31st.
Read Our Latest Analysis on CYBN
Cybin Stock Down 0.2 %
The firm has a market capitalization of $4.01 billion, a P/E ratio of -48.55 and a beta of 0.41.
Cybin (NYSE:CYBN - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.01) earnings per share for the quarter. On average, equities analysts forecast that Cybin Inc. will post -2.85 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. PEAK6 Investments LLC acquired a new position in Cybin during the first quarter valued at approximately $95,000. AWM Investment Company Inc. bought a new position in shares of Cybin during the first quarter worth $930,000. Ikarian Capital LLC acquired a new position in shares of Cybin in the 1st quarter valued at $5,770,000. RA Capital Management L.P. bought a new stake in shares of Cybin in the 1st quarter valued at $24,041,000. Finally, Rosalind Advisors Inc. raised its stake in Cybin by 38.3% during the 2nd quarter. Rosalind Advisors Inc. now owns 19,300,000 shares of the company's stock worth $5,230,000 after buying an additional 5,340,000 shares during the period. Institutional investors and hedge funds own 17.94% of the company's stock.
About Cybin
(
Get Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.
Further Reading
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
